Insider sale and plan details
Neville Everett, an officer at Cigna Group (NYSE: CI), sold 1,719 shares of the companys common stock on March 2, 2026, at a price of $288.91 per share. The transaction generated $496,636 in proceeds. The disposition was executed pursuant to a pre-arranged Rule 10b5-1 trading plan that Everett adopted on May 22, 2025.
The sale price of $288.91 was modestly above the then-current Cigna share price of $283.93. At that valuation snapshot, the healthcare provider was trading at a price-to-earnings ratio of 12.76.
Additional February 27 transactions
Earlier, on February 27, 2026, Everett was involved in a set of other equity transactions. Records show acquisitions of 2,602 shares and 2,678 shares of Cigna common stock that were recorded with a value of $0. On the same day, Everett disposed of 883 shares and 517 shares to satisfy tax obligations; those shares were sold at $287.55 per share, producing $402,570 in proceeds.
Option grant and vesting schedule
Also on February 27, 2026, Everett received a grant of 4,127 options to purchase common stock at an exercise price of $287.5475 per share. The options are scheduled to vest in three equal annual installments beginning March 1, 2027, and they carry an expiration date of February 27, 2036.
Valuation and investor research context
An InvestingPro analysis included with the filings characterized Cigna as appearing undervalued at its then-current levels. The firm also noted that Cigna has maintained dividend payments for 45 consecutive years.
Recent operating performance and leadership update
In related corporate disclosures, Cigna reported fourth-quarter 2025 results that exceeded consensus expectations. The company posted earnings per share of $8.08 compared with a forecast of $7.88. Revenue for the quarter was $72.47 billion versus a projected $70.31 billion. The company attributed the stronger performance in part to growth in its specialty pharmacy segment as well as to innovative healthcare offerings.
Cigna also announced a board-approved leadership transition. Brian Evanko will succeed David M. Cordani as chief executive officer effective July 1, 2026. Following the handover, Cordani will move into the role of executive chair of the Board of Directors.
Analyst action
Separately, TD Cowen raised its price target on Cigna to $338 while maintaining a Buy rating. The firm cited the resolution of concerns related to stop loss and pharmacy benefit manager reform as factors influencing its view.
The combination of insider transactions, recent financial results, and a scheduled leadership change comprise the primary developments disclosed in the filings and accompanying research notes for the period.